论文部分内容阅读
目的观察使用胺碘酮治疗充血性心力衰竭合并室性心律失常患者的临床疗效。方法选取我院于2008年4月～2009年4月收治的84例充血性心力衰竭合并室性心律失常的患者,对照组进行常规治疗,并应用倍他乐克;观察组在常规治疗的基础上应用胺碘酮。观察两组患者在不良用药反应、心脏性猝死、抗室性心律失常、心力衰竭再住院率以及左室射血分数上的不同,进行比较分析。结果对照组与观察组在不良用药反应上的比较差异P>0.05,不具统计学意义。在抗心律失常与心功能的改善程度上,观察组明显高于对照组,比较差异P<0.05,具有统计学意义。同时,观察组的病死率与再住院率显著低于对照组,比较差异P<0.05,具有统计学意义。结论在充血性心力衰竭合并室性心律失常患者的治疗中,胺碘酮可以显著改善心功能,不良反应少,有着积极的治疗效果,适于在临床领域得到进一步的推广和应用。
Objective To observe the clinical efficacy of amiodarone in patients with congestive heart failure and ventricular arrhythmia. Methods Eighty-four patients with congestive heart failure and ventricular arrhythmia admitted from April 2008 to April 2009 in our hospital were selected. Patients in the control group received routine treatment and metoprolol. The observation group was treated on the basis of routine treatment On the application of amiodarone. The differences of adverse drug reactions, sudden cardiac death, anti-ventricular arrhythmia, heart failure rehospitalization rate and left ventricular ejection fraction were observed in two groups of patients for comparative analysis. Results The difference between the control group and the observation group in adverse drug reactions was P> 0.05, not statistically significant. In the anti-arrhythmia and cardiac function improvement, the observation group was significantly higher than the control group, the difference was P <0.05, with statistical significance. At the same time, the mortality and rehospitalization rate in the observation group were significantly lower than those in the control group, with a significant difference P <0.05, with statistical significance. Conclusions Amiodarone can significantly improve cardiac function and less adverse reactions in patients with congestive heart failure and ventricular arrhythmia. It has a positive therapeutic effect and is suitable for further promotion and application in the clinical field.